BR0008054A - Forma cristalina de eplerenona - Google Patents

Forma cristalina de eplerenona

Info

Publication number
BR0008054A
BR0008054A BR0008054-3A BR0008054A BR0008054A BR 0008054 A BR0008054 A BR 0008054A BR 0008054 A BR0008054 A BR 0008054A BR 0008054 A BR0008054 A BR 0008054A
Authority
BR
Brazil
Prior art keywords
eplerenone
crystalline form
preparing
aldosterone
amount
Prior art date
Application number
BR0008054-3A
Other languages
English (en)
Inventor
Kathleen P Barton
Henry T Gaud
Scott Ganser
Clay R Little
Partha S Mudipalli
Thomas B Borschardt
Marlon V Carlos
Subhash Desai
Leonard J Ferro
Mark A Pietz
Daniel R Pilipauskas
Yuen-Lung L Sing
Glenn L Stahl
Joseph J Wieczorek
Chris Y Yan
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0008054A publication Critical patent/BR0008054A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

"FORMA CRISTALINA DE EPLERENONA". Providencia-se uma nova forma cristalina (Forma L) da droga eplerenona antagonista do receptor de aldosterona, com estabilidade física relativamente alta a temperaturas normais de armazenagem e uso. São também providenciadas composições farmacêuticas compreendendo eplerenona na Forma L, opcionalmente acompanhadas de uma ou mais formas de eplerenona no estado sólido, numa quantidade de dosagem unitária total de eplerenona de cerca de 10 a cerca de 1000 mg, e ainda, compreendendo um ou mais excipientes farmaceuticamente aceitáveis. São providenciados processos para preparar eplerenona na Forma L e para preparar composições compreendendo eplerenona na Forma L, bem como um método para profilaxia e/ou tratamento de uma condição ou distúrbio mediados por aldosterona, compreendendo a administração a um indivíduo, de uma quantidade terapeuticamente eficaz de eplerenona, onde pelo menos uma fração da eplerenona presente se trata de eplerenona na Forma L.
BR0008054-3A 1999-12-08 2000-12-04 Forma cristalina de eplerenona BR0008054A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16980799P 1999-12-08 1999-12-08
US16970799P 1999-12-08 1999-12-08
US16968399P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08
US16955699P 1999-12-08 1999-12-08
US16960899P 1999-12-08 1999-12-08
PCT/US2000/030178 WO2001041535A2 (en) 1999-12-08 2000-12-04 Eplerenone crystalline form

Publications (1)

Publication Number Publication Date
BR0008054A true BR0008054A (pt) 2002-03-12

Family

ID=27558586

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008054-3A BR0008054A (pt) 1999-12-08 2000-12-04 Forma cristalina de eplerenona

Country Status (19)

Country Link
US (1) US20090149431A1 (pt)
EP (1) EP1175434A2 (pt)
JP (2) JP4219105B2 (pt)
KR (1) KR100584104B1 (pt)
CN (1) CN100413881C (pt)
AR (1) AR074665A2 (pt)
AU (1) AU2041101A (pt)
BR (1) BR0008054A (pt)
CA (1) CA2362845A1 (pt)
CO (1) CO5280205A1 (pt)
EA (1) EA008449B1 (pt)
HK (1) HK1057220A1 (pt)
HU (1) HUP0201457A3 (pt)
IL (2) IL144757A0 (pt)
MY (1) MY143571A (pt)
NO (1) NO20013857L (pt)
NZ (1) NZ513962A (pt)
PE (1) PE20010918A1 (pt)
WO (1) WO2001041535A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20010821A1 (it) * 2001-04-17 2002-10-17 Gienne Pharma S P A Impiego di composti derivati dallo spirolattone per inibire l'azione pro-fibrigenetica delle cellule stellate epatiche e delle cellule musco
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
CA2796307A1 (en) 2010-05-10 2011-11-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
CN104844681B (zh) * 2014-02-13 2016-06-01 合肥久诺医药科技有限公司 一种l晶型依普利酮的精制方法
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
US20190262363A1 (en) 2016-07-26 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
IL124631A (en) * 1995-12-11 2004-03-28 Searle & Co Processes for preparations of steroids and intermediates useful therein
IL130182A0 (en) * 1996-12-11 2000-06-01 Searle & Co Processes for preparation of 9,11-epoxy steroids and intermediates useful therein
CN1229141C (zh) * 1999-03-05 2005-11-30 G.D.瑟尔有限公司 用于治疗心血管病的血管紧张素转化酶抑制剂和环氧－甾族醛固酮拮抗剂的组合物

Also Published As

Publication number Publication date
JP2003515611A (ja) 2003-05-07
CA2362845A1 (en) 2001-06-14
NO20013857D0 (no) 2001-08-08
NO20013857L (no) 2001-10-08
CO5280205A1 (es) 2003-05-30
WO2001041535A2 (en) 2001-06-14
IL144757A (en) 2007-07-24
US20090149431A1 (en) 2009-06-11
EP1175434A2 (en) 2002-01-30
HUP0201457A3 (en) 2003-07-28
AR074665A2 (es) 2011-02-02
JP2007016043A (ja) 2007-01-25
PE20010918A1 (es) 2001-09-10
KR20020003192A (ko) 2002-01-10
EA200100869A1 (ru) 2002-04-25
EA008449B1 (ru) 2007-06-29
CN1433427A (zh) 2003-07-30
MY143571A (en) 2011-05-31
NZ513962A (en) 2004-08-27
JP4219105B2 (ja) 2009-02-04
CN100413881C (zh) 2008-08-27
AU2041101A (en) 2001-06-18
WO2001041535A3 (en) 2001-11-22
WO2001041535A9 (en) 2002-07-04
KR100584104B1 (ko) 2006-05-30
IL144757A0 (en) 2002-06-30
HK1057220A1 (en) 2004-03-19
HUP0201457A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
Hazen et al. Management of necrotizing vasculitis with colchicine: Improvement in patients with cutaneous lesions and Behçet's syndrome
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
KR20010015707A (ko) 의약
Fisher et al. (±)-cis-2-Methyl-spiro (1, 3-oxathiolane-5, 3′) quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
JP2002523370A5 (pt)
CN102395275A (zh) 用四环吡嗪并吲哚治疗多发性硬化症的方法
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
AR074665A2 (es) Formula cristalina no solvatada de eplerenona (forma l), sustancia farmacologica y composicion farmaceutica que la comprenden
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
HUP0400553A2 (hu) Gyógyászati készítmények
BR0008057A (pt) Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada
Sheffer et al. Cetirizine: antiallergic therapy beyond traditional H1 antihistamines
WO2004096118B1 (en) Composition for improving cognition and memory
DK1027053T3 (da) Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser
WO2007087344A3 (en) Anti-histamine compositions and use thereof
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
RU2013105513A (ru) Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи
US6153635A (en) Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate
BRPI0415322A (pt) composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina
EP0532512B1 (en) Use of platelet activating factor antagonists as anti-pruritic agents
UA123780C2 (uk) Лікування екземи кистей
BR0012822A (pt) Formulação farmacêutica, e, forma de dosagem em tablete
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
KR101465277B1 (ko) 무스카린 ｍ1, ｍ2 및 ｍ3 수용체 선택적 억제제 제조에 있어서의 10-[(3ｒ)-1-아자바이사이클로[2.2.2]옥트-3-일메틸]-10ｈ-페노티아진 용도

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]